Performances of CA125, LAMC2 in diagnosis of CA19.9-negative PDAC patients
| Training set | Validation set | |||
|---|---|---|---|---|
| AUC (95% CI) | P | AUC (95% CI) | P | |
| Benign vs. all PDAC | ||||
| CA19.9 | 0.59 (0.46–0.72) | 0.2 | 0.54 (0.41–0.66) | 0.5 |
| CA125 | 0.73 (0.62–0.84) | 0.0003 | 0.78 (0.67–0.88) | <0.0001 |
| LAMC2 | 0.76 (0.65–0.86) | <0.0001 | 0.64 (0.53–0.76) | 0.02 |
| CA125 + LAMC2 | 0.81 (0.71–0.90) | <0.0001 | 0.76 (0.66–0.86) | <0.0001 |
| CP vs. early-stage PDAC | ||||
| CA19.9 | 0.53 (0.37–0.69) | 0.7 | 0.52 (0.35–0.70) | 0.8 |
| CA125 | 0.72 (0.58–0.86) | 0.007 | 0.77 (0.64–0.90) | 0.002 |
| LAMC2 | 0.79 (0.67–0.91) | 0.0002 | 0.62 (0.44–0.79) | 0.2 |
| CA125 + LAMC2 | 0.84 (0.73–0.95) | <0.0001 | 0.73 (0.57–0.89) | 0.01 |
P values are calculated by the Wilcoxon test in the comparison between benign and cancer groups.